Navigation Links
MS Drug Development Agreement Based on WEHI's Medicinal Chemistry
Date:7/2/2008

MELBOURNE, Australia, July 2 /PRNewswire/ -- Research conducted at The Walter and Eliza Hall Institute (WEHI) has contributed significantly to a major licensing agreement signed between Australian biotechnology company, Bionomics, (ASX:BNO) and Germany-based pharmaceutical company, Merck Serono.

Under the Development and Licensing Agreement, Merck Serono will seek to develop new treatments for multiple sclerosis (MS) and other autoimmune conditions. These prospective treatments will be based upon compounds from Bionomics' Kv1.3 program, which WEHI had a fundamental role in developing.

The Kv1.3 program has its origins in the late 1990s, when WEHI's Dr Jonathan Baell and collaborators discovered that certain derivatives of a natural product called khellinone could block a potassium channel called Kv1.3. This potassium channel selectively inhibits autoreactive T cells, such as those that attack the myelin sheath in people with MS.

Dr Baell says, "Our research in this area had a rocky start, but when our first patents were published in 2003, Start-Up Australia approached us with an interest in licensing the intellectual property. This came to fruition in late 2004 through their investee company, Iliad, which was able to resource the medicinal chemistry effort required."

In 2005, Iliad was acquired by Bionomics, which further accelerated progress with the program.

Dr Baell continues, "There was a great meeting of minds between chemists from WEHI and Bionomics, leading to a significant expansion of the patent portfolio. Bionomics also established an in-house biology platform that effectively serviced the whole program."

"During the whole process, every scientist at WEHI and Bionomics maintained a focus upon what we were trying to achieve: a treatment for MS, a debilitating disease that is tragically common among young adults. Our progress and achievements to date demonstrate that with intense tenacity and a collaborative approach, academic drug discovery programs can produce great outcomes."

WEHI's research achievements were recognised on a national basis by the Royal Australian Chemical Institute with the 2004 Biota Award to Dr Baell for medicinal chemistry and the award of an NHMRC Industry Fellowship to Dr Andrew Harvey, who became an important driver of the program, along with Bionomics' medicinal chemistry colleagues, Drs Flynn, Chaplin, Paul and Mould.

For further information, contact

Brad Allan,

WEHI Communications Manager:

tel +61 3 9345 2345;

mobile 0403036116


'/>"/>
SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
2. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
3. Cystic Fibrosis - Axentis Pharma Takes Over Patents and Continues Development of Innovative Platform Technology
4. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
5. U.S. Commerce Secretary Gutierrez Cuts Ribbon on MaxWell Biocorporations New Pharmaceutical Development Center and Quality Control Laboratory in Ukraine
6. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
7. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
8. Discovery by UC Riverside physicists could enable development of faster computers
9. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
10. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
11. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):